SIWA Therapeutics is a biotechnology startup founded in 2006 and based in the United States. The company is focused on developing biological therapies that target the aging process. Their leading product, SIWA 318H, is a humanized monoclonal antibody designed to eliminate senescent cells (SCs), which are associated with age-related conditions and degenerative diseases.
By specifically targeting these detrimental cells that disrupt normal cellular functions, SIWA 318H has shown promise in extending both healthspan and lifespan. The startup received a $1.63M venture round investment on 22 May 2017, signaling investor confidence in their innovative approach to addressing age-related health issues.
SIWA Therapeutics operates in the biotechnology and health and wellness industries, positioning itself at the forefront of pioneering advancements in anti-aging therapies. The company's commitment to leveraging biological interventions to combat age-related ailments presents an enticing opportunity for venture capital investors seeking to support groundbreaking solutions in the healthcare sector.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $1.63M | - | 22 May 2017 |
No recent news or press coverage available for SIWA Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
